Optimum Investment Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Optimum Investment Advisors’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-14,425	Closed	-$729K	–	279
2015 Q4	$729K	Sell	14,425 -1,605	-10%	-$79.3K	0.28%	109
2015 Q3	$733K	Buy	+16,030	New	+$896K	0.3%	103
2015 Q1	$843K	Buy	15,295 +3,015	+25%	+$163K	0.27%	104
2014 Q4	$616K	Buy	12,280 +4,035	+49%	+$197K	0.2%	134
2014 Q3	$381K	Buy	8,245 +750	+10%	+$33.8K	0.13%	168
2014 Q2	$328K	Buy	7,495 +630	+9%	+$25.5K	0.11%	190
2014 Q1	$286K	Buy	6,865 +4,640	+209%	+$199K	0.11%	190
2013 Q4	$82K	Buy	2,225 +900	+68%	+$32.3K	0.03%	320
2013 Q3	$46K	Buy	+1,325	New	+$43.9K	0.02%	382

Other funds holding PBE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TAM

Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return

HBT

Hills Bank & Trust North Liberty, Iowa $2.07B AUM 13.46% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Optimum Investment Advisors's PBE Position: Q1 2016 in Review

Optimum Investment Advisors sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2016, closing a stake of 14,425 shares — an estimated $729K sold.

Optimum Investment Advisors first reported a position in PBE in Q3 2013 and held it in 9 quarters. The position peaked at $843K in Q1 2015. 71 funds tracked by Wall St. Rank hold PBE as of Q1 2016.

Optimum Investment Advisors reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2016 after selling out during the quarter.
Optimum Investment Advisors sold 14,425 Invesco Biotechnology & Genome ETF shares in Q1 2016, an estimated $729K.
Optimum Investment Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q3 2013 and held it in 9 quarters.
Optimum Investment Advisors's Invesco Biotechnology & Genome ETF position peaked at $843K in Q1 2015.
71 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2016.

Based on Optimum Investment Advisors's 13F filing for Q1 2016, filed 12 May 2016.